Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author holds a long position in BFLY.

← Back to Free Index

BFLY

Analysis as of: 2026-04-21

Butterfly Network, Inc.

Butterfly sells handheld semiconductor ultrasound devices, cloud workflow software, and related services to clinicians, health systems, medical schools, and veterinarians.

ai hardware healthcare medical devices software

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Portable imaging with real platform upside

A proprietary ultrasound chip and regulated workflow stack give this small-cap medtech more optionality than a typical device vendor. The bull case depends on turning recent proof points in software, home-based care, and partner licensing into repeatable revenue.

Analysis

Thesis

Butterfly has a credible path from niche handheld ultrasound vendor to regulated imaging platform: if core probe growth stays solid and newer layers like enterprise workflow, home-based care, and embedded licensing become repeatable, revenue can compound well above normal medtech without needing a pure software fantasy multiple.

Last Economy Alignment

Butterfly benefits as AI lowers training friction and makes ultrasound more ubiquitous, while its chip, regulated workflow, and trust layers keep it from being a pure software commodity. The cap on the score is incumbent bundling and the still-early proof of repeatable platform monetization.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

2.7x (from 5 most recent analyses)

Reasoning

I underwrite solid compounding, not a moonshot. The key is mix shift: more enterprise workflow revenue, repeatable partner licensing, and a real home-based care channel can make Butterfly look less like a one-off probe vendor and more like a regulated imaging stack. The stock can work without a heroic rerating, but only if newer revenue streams prove repeatable across customers.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The main risk is not technology failure but incomplete business-model evolution. Butterfly can keep growing as a differentiated handheld ultrasound company while still failing to become a higher-value workflow and licensing platform. If regulatory cadence slows, suppliers constrain scaling, or newer revenue streams stay lumpy, the current premium valuation leaves limited room for disappointment.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

On April 16, 2026, management set April 30, 2026 for Q1 results, making durability of the strong Q4 print the immediate gating event.
No new HomeCare contract or Beam Steering API launch was disclosed in the last 7-10 days, so the thesis remains waiting for commercial confirmation rather than adding new evidence.
Shares stayed near the 52-week high into the Q1 print, which raises expectations risk even though the operating setup is still improving.

Thesis update

The core thesis is intact, but it is less conceptual than before: Embedded has now shown real revenue and regulated AI scope has expanded. The remaining debate has shifted from possibility to repeatability.

Forecast update

Upside now depends more on execution than rerating because the stock has already repriced a meaningful part of the platform option.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.42

They control a specialized ultrasound chip plus the clinical software and security layers around it, so AI can make scanning easier and widen adoption without instantly giving away all the value. The risk is that bigger imaging vendors bundle similar tools faster, leaving Butterfly as a clever device rather than the trusted control point.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$5.56

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research